Sarcomatoid carcinoma of the renal pelvis: Experience of multiple cases over a ten-year period

SHANWEN CHEN¹, GEMING CHEN¹, DAN XIA¹, JUN LI², SHUO WANG¹, BAIHUA SHEN¹ and BAIYE JIN¹

Departments of ¹Urology and ²Pathology, The First Affiliated Hospital, Medical School of Zhejiang University, Hangzhou, Zhejiang 310031, P.R. China

Received January 1, 2013; Accepted May 15, 2013

DOI: 10.3892/ol.2013.1396

Abstract. Sarcomatoid carcinoma of the renal pelvis is a rare clinical entity. To the best of our knowledge, only 14 cases of this type of neoplasm have been reported in the literature to date. In the present study, the records at The First Affiliated Hospital, Medicine School of Zhejiang University (Hangzhou, Zhejiang, China) between 2000 and 2010 were reviewed to identify patients with primary renal pelvis sarcomatoid carcinoma (RPSC). A particular emphasis was placed on the treatment, recurrence and survival outcome. Eight patients with RPSC were identified and treated with nephrectomy or nephroureterectomy. All of the patients presented with Grade 3 RPSC. According to the TNM classification system, 2 patients were in stage pT2, 5 in stage pT3 and 1 in stage pT4. Adjuvant chemotherapy was administered to four patients, and the mean follow-up period was 27.5±41.0 months. In total, 6 patients succumbed to the disease with a mean survival time of 7.7±5.3 months (range, 1-18 months), while 2 patients were free of disease at 54 and 120 months, respectively, following treatment. The mean disease-specific survival time was 27.5±41.0 months and the 1-year recurrence-free survival, 1-year survival and overall survival rates were 37.5, 37.5 and 25%, respectively. The present analysis suggests a poor prognosis for the majority of RPSC patients, most likely resulting from the advanced stage of the disease at diagnosis and a poor response to systemic therapy. To improve the survival rate of RPSC, it is therefore essential to perform an early diagnosis and early radical surgery. Intravesical instillation is not essential following surgery.

Introduction

Transitional cell carcinoma is the most common histological type of urinary tract cancer. Squamous cell carcinoma and adenocarcinoma form the second and third most common histological types, respectively. Renal pelvis sarcomatoid carcinoma (RPSC) is an extremely rare variant of urinary tract cancer, which possesses a high-grade malignant neoplasm and a poor prognosis. To the best of our knowledge, only 14 cases of RPSC have been reported in the literature to date, usually as case reports or small series (1-9). In the present study, we report our experience with 8 cases of RPSC. A particular emphasis was placed on the treatment, recurrence and survival outcome of RPSC.

Patients and methods

Patients and methods. Between January 2000 and December 2010, 8 males with RPSC (age range, 38-78 years; mean age, 65.3±14.0 years) were registered in the surgical pathology files at The First Affiliated Hospital, Medicine School of Zhejiang University (Hangzhou, Zhejiang, China), including 1 previously reported case (10). Formalin-fixed paraffin-embedded tissue sections stained with hematoxylin and eosin were available for examination for each case. The pathological features were retrospectively evaluated and confirmed by a urological pathologist. The institutional review board of the The First Affiliated Hospital, Medicine School of Zhejiang University approved the retrospective study. Written informed consent was obtained from the patient or patient’s family.

Results

Diagnosis. Of the 342 evaluated patients that were treated for tumors of the renal pelvis, 8 (2.3%) were diagnosed...
with primary RPSC. The tumor characteristics and patient outcomes are shown in Table I. Among the 8 patients diagnosed with sarcomatoid carcinoma, the male-to-female ratio was 8:0. The symptoms observed in the 8 patients included hematuria in 7 cases and abdominal pain in 1 case. A tumor of the renal pelvis was identified in all patients by contrast-enhanced computed tomography. Malignancy was diagnosed cytologically with renal pelvis lavage in 2 cases (including 1 case with sarcomatoid carcinoma) prior to surgery. Immunohistochemical studies confirmed the diagnosis of sarcomatoid carcinoma. Prior to surgery, 3 patients were in stage pT2 and 5 were in stage pT3, according to the TNM classification system.

Of the 8 patients diagnosed with RPSC, 3 patients were treated with nephrectomy (2 patients with nephrectomy plus chemotherapy) and 5 patients with nephroureterectomy (2 patients with nephroureterectomy plus chemotherapy). The gross appearance of the sarcomatoid carcinoma was described in 8 cases. The mean tumor size was 5.8±4.5 cm (range, 1.5-16.0 cm) at the greatest dimension. In total, 5 lesions were polypoid and 3 were nodular. A pure spindle cell carcinoma without any apparent epithelial components was noted in 1 case, spindle and transitional cell carcinoma in 4 cases and spindle and squamous cell carcinoma in 3 cases. According to the TNM classification system, 2 patients were now diagnosed with stage pT2, 5 with stage pT3 and 1 with stage pT4.

Survival. The mean follow-up time was 27.5±14.0 months. A total of 6 patients succumbed to the disease with a mean survival time of 7.7±5.3 months (range, 1-18 months; Table I), while 2 patients (cases 4 and 7) were free of disease at 54 and 120 months, respectively. The mean disease-specific survival time was 27.5±41.0 months. The 1-year recurrence-free survival, 1-year survival and overall survival rates were 37.5, 37.5 and 25%, respectively. A comparison between the patients who underwent surgery alone and those who underwent surgery plus chemotherapy demonstrated no evident difference in survival (Table II).

Discussion

Sarcomatoid carcinoma has been reported in a variety of organs, including the urinary bladder (11,12), kidney (13) and female genital tract (14). RPSC is an extremely rare entity, with only 14 confirmed cases reported in the literature since 1961 (1-9).

The characteristics of the 22 reported patients (including the patients examined in the present study) with RPSC are shown in Table I and Table III. RPSC was more common in males than females (4:1 ratio in previously reported studies, 8:0 ratio in the present study) and more common in the right side compared with the left side (5:2 ratio in previously reported studies, 5:3 ratio in the present study). The most common symptom of RPSC was gross hematuria.

The prognosis for patients diagnosed with RPSC is poor. Several factors contribute to this poor prognosis, including diagnosis at an advanced stage of the disease, high-grade features, a large tumor and a short progression time despite additional therapy. The previously reported 13 cases of RPSC were of metastatic disease or advanced tumor involvement...
of the renal parenchyma, which had an extremely poor prognosis (1-8). Among these 13 patients, 8 succumbed to disease within 2 years of diagnosis (range, 2-20 months) and adjuvant chemotherapy provided no response or survival advantage when used (7). Thiel et al reported the 14th case of urothelial-confined and organ-confined RPSC, which presented without recurrence for >16 months (9). A nephrectomy or nephroureterectomy was performed in all of the cases of RPSC examined in the present study; however, 6 patients (5 in TNM stage pT3 and 1 in TNM stage pT4) succumbed to the disease within 18 months (range, 1-18 months; mean, 7.7 months). The patients in the present study (TNM stage pT3 or pT4 disease) rarely had a prolonged survival time despite undergoing surgery. Of the 2 patients (TNM stage pT2) who were alive without recurrence at the final follow-up, 1 did not receive chemotherapy. Adjuvant chemotherapy exerted a minimal effect in the present study. Due to the limited number of patients and the nature of a retrospective analysis, a conclusion should not be made with regard to the role of adjuvant chemotherapy, as the patients treated this way may have had a more advanced stage of disease resulting in a selection bias. In addition, no patient in this study developed recurrence in the bladder, supporting the hypothesis that non-urothelial carcinoma has a different tumor

Table II. Patient outcomes of the cases of RPSC reported in the present study.

| Variable | All | Surgery alone | Surgery plus chemotherapy |
|----------|-----|---------------|--------------------------|
| Alive, n | 2   | 1             | 1                        |
| NED, n   | 2   | 1             | 1                        |
| Follow-up, months | 27.5 | 20.8 | 34.3 |
| Follow-up of patients who remained alive, months | 87.0 | 54.0 | 120.0 |
| Follow-up of patients who succumbed to disease, months | 7.7 | 9.7 | 5.7 |
| Survival, months | 27.5 | 20.8 | 34.3 |
| 1-year survival rate, % | 37.5 | 50 | 25 |
| RFS, months | 25.8 | 19.8 | 31.8 |
| 1-year RFS rate, % | 37.5 | 50 | 25 |
| DSS, months | 27.5 | 20.8 | 34.3 |
| 1-year DSS rate, % | 37.5 | 50 | 25 |

*Numbers represent mean values, unless otherwise specified. NED, no evidence of disease; RFS, recurrence-free survival; DSS, disease-specific survival; RPSC, renal pelvis sarcomatoid carcinoma.*

Table III. Patient characteristics of previously reported cases of RPSC.

| Patient no. | First author/s (ref.) | Age/gender/side | Histology | T/Fu/Mo |
|------------|----------------------|----------------|-----------|---------|
| 1          | Fauci et al (1)      | 61/F/R         | TCC/pleomorphic | Nu/NED/6 |
| 2          | Tarry et al (2)      | 61/F/R         | TCC/giant-cell tumor-like | Nu/NED/20 |
| 3          | Piscioli et al (3)   | 62/M/R         | TCC/rhabdomyosarcoma tumor-like | Nu/NR/NR |
| 4          | Wick et al (4)       | 45/M/L         | TCC/anaplastic-spindle | Nu/STD/22 |
| 5          | Wick et al (4)       | 65/F/R         | SQ/spindle | Nu/STD/7 |
| 6          | Tajima and Aizawa (5) | 66/M/R       | TCC/adenocarcinoma/anaplastic-spindle | Nu/NED/12 |
| 7          | Suster and Robinson (6) | 85/M/R     | Spindle | Nu/NED/3 |
| 8          | Lopez-Beltran et al (7) | 65/M/L    | Spindle/anaplastic | N/STD/20 |
| 9          | Lopez-Beltran et al (7) | 66/M/R    | Spindle/anaplastic | N/STD/6 |
| 10         | Lopez-Beltran et al (7) | 66/F/R    | Spindle/anaplastic | N/STD/18 |
| 11         | Lopez-Beltran et al (7) | 82/F/R    | Spindle/myxoid | Nu/STD/6 |
| 12         | Lopez-Beltran et al (7) | 79/M/R    | Spindle/myxoid | N/STD/6 |
| 13         | Hisataki et al (8)   | 43/F/L         | TCC/spindle | N/STD/14 |
| 14         | Thiel et al (9)      | 65/M/L         | Spindle/osteoclast-type giant cells | Nu/NED/16 |

F, female; M, male; R, right; L, left; TCC, transitional cell carcinoma; SQ, squamous differentiation; T/Fu/Mo, treatment/follow-up/months; N, nephrectomy; Nu, nephroureterectomy; NED, no evidence of disease; NR, not reported; STD, succumbed to disease; RPSC, renal pelvis sarcomatoid carcinoma.
briology compared with urothelial carcinoma. Therefore, intravesical instillation is not essential following surgery.

As RPSC is known for its aggressive nature, insensitivity to adjuvant therapy and adverse outcomes, it is essential to conduct an early diagnosis and early radical surgery to improve the survival outcome (7,8). In the present study, the 2 cases of urothelial-confined and organ-confined RPSC (cases 4 and 7) did not recur for >4 years following radical surgery. Efforts aimed at improving the accuracy of diagnosis at presentation and the consequent treatment strategies are required. The main obstacle for the accurate diagnosis and treatment of RPSC is that the presentation of non-urothelial tumors is usually similar to that of urothelial tumors. Any findings that suggest the possibility of RPSC should subsequently invoke a more thorough investigation implementing a repeat biopsy with specific immunohistochemical stains. These findings may include the following: abnormal cytology results that are incongruent with tumors of the renal pelvis (as in the present study, immunocytochemistry with markers of sarcomatoid carcinoma aids discrimination); atypical radiological characteristics or any evidence of metastatic disease despite the radiological appearance of small-volume disease. Following a clinical presentation that suggests RPSC, neoadjuvant strategies may aid in the identification of those patients who are the best candidates for surgery and also aid in avoiding unnecessary surgery in patients where it is likely that their disease will progress rapidly. Patients with TNM stage pT2 should be treated with nephroureterectomy, patients with TNM stage pT3 should be treated with nephrectomy and patients with TNM stage T4 should avoid surgery. However, this hypothesis remains to be verified.

In conclusion, RPSC is rare. The present study analysis suggests a poor prognosis for the majority of patients with RPSC, most likely as a result of the advanced stage of the disease at diagnosis and the poor response to systemic therapy. It is essential to conduct an early diagnosis and early radical surgery to improve the survival outcome. Intravesical instillation is not essential following surgery.

Acknowledgements

This study was supported by a grant from the National Key Clinical Specialty Construction Project of China.

References

1. Fauci PA Jr, Therhag HG and Davis JE: Carcinomas of the renal pelvis. J Urol 85: 897-902, 1961.
2. Tarry WF, Morabito RA and Belis JA: Carcinomas of the renal pelvis with extension into the renal vein and inferior vena cava. J Urol 128: 582-585, 1982.
3. Piscioli F, Bondi A, Scappini P and Luciani L: ‘True’ sarcomatoid carcinoma of the renal pelvis. First case report with immunocytochemical study. Eur Urol 10: 350-355, 1984.
4. Wick MR, Perrone TL and Burke BA: Sarcomatoid transitional cell carcinomas of the renal pelvis. An ultrastructural and immunohistochemical study. Arch Pathol Lab Med 109: 55-58, 1985.
5. Tajima Y and Aizawa M: Unusual renal pelvic tumor containing transitional cell carcinoma, adenocarcinoma and sarcomatoid elements (so-called sarcomatoid carcinoma of the renal pelvis). A case report and review of the literature. Acta Pathol Jpn 38: 805-814, 1988.
6. Suster S and Robinson MJ: Spindle cell carcinoma of the renal pelvis. Immunohistochemical and ultrastructural study of a case demonstrating coexpression of keratin and vimentin intermediate filaments. Arch Pathol Lab Med 113: 404-408, 1989.
7. Lopez-Beltran A, Escudero AL, Cavazzana AO, Spagnoli LG and Vicioso-Recio L: Sarcomatoid transitional cell carcinoma of the renal pelvis. A report of five cases with clinical, pathological, immunohistochemical and DNA ploidy analysis. Pathol Res Pract 192: 1218-1224, 1996.
8. Hisataki T, Takahashi A, Taguchi K, Shimizu T, Suzuki K, Takatsuka K and Iwaki H: Sarcomatoid transitional cell carcinoma originating from a duplicated renal pelvis. Int J Urol 8: 704-706, 2001.
9. Thiel DD, Igel TC and Wu KJ: Sarcomatoid carcinoma of transitional cell origin confined to renal pelvis. Urology 67: 622.e9-622.e11, 2006.
10. Chen GM, Chen SW, Xia D, Li J, Yan S and Jin BY: Sarcomatoid carcinoma of the renal pelvis in duplex kidney. Chin Med J (Engl) 124: 2074-2076, 2011.
11. Arita N, Ishida M, Yoshida K, Kagotani A, Iwamoto N, Iwai M and Okabe H: Sarcomatoid variant of urothelial carcinoma: Cytological analysis of three cases. Oncol Lett 5: 49-52, 2013.
12. Cheng L, Zhang S, Alexander R, Maclellan GT, Hodges KB, Harrison BT, Lopez-Beltran A and Montironi R: Sarcomatoid carcinoma of the urinary bladder: the final common pathway of urothelial carcinoma dedifferentiation. Am J Surg Pathol 35: e34-e46, 2011.
13. de Peralta-Venturina M, Moch H, Amin M, Tamboli P, Hailemariam S, Mihatsch M, Juvin J, Stricker H, Ro JY and Amin MB: Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 25: 275-284, 2001.
14. Steeper TA, Piscioli F and Rosai J: Squamous cell carcinoma with sarcoma-like stroma of the female genital tract. Clinicopathologic study of four cases. Cancer 52: 890-898, 1983.